Humacyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HUMA | BSEM | VANI | BCDA | OBIO | CELU | |
|---|---|---|---|---|---|---|
| Market cap | 108.23M | 45.56M | 107.34M | 15.44M | 355.22M | 47.70M |
| P/E (TTM) | — | 2.8 | — | — | — | — |
| Forward P/E | -1.6 | 8.4 | -3.4 | -1.8 | -3.9 | -2.6 |
| Price/book | 3.4 | 1.6 | 5.6 | 5.7 | 18.4 | -1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −76.99% | −48.09% | −7.75% | −34.19% | +86.52% | −23.53% |
| Today | −3.87% | −1.21% | −4.80% | −1.92% | −0.67% | −5.77% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HUMA news ›Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Humacyte targets an FDA submission this quarter to expand the Symvess label to hemodialysis access. V012 results and two previously completed Phase 3 hemodialysis-access trials form the clinical foundation for a planned supplemental…
POTM: Scott Coward and Paul Kuznik Join Humacyte's Board of Directors
“We are delighted to welcome two distinguished commercialization and life science leaders to the Humacyte Board as we continue to expand our ongoing Symvess launch and prepare for our planned commercial launch of the ATEV in the dialysis…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
biobuzz.io1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.